Advanced Accelerator Applications Provides Update on Lutathera and Somakit
Advanced Accelerator Applications today announced both updated data from the pivotal Phase 3 NETTER-1 study investigating the treatment of Lutathera (177-Lu-Dotatate) in patients with inoperable, progressive, somatostatin receptor positive midgut neuroendocrine tumors (midgut NETs) as well as Prescr...
AAA reaches halfway recruitment milestone of cancer patients in Lutathera® Pivotal Phase III trial
Advanced Accelerator Applications has reached the 100-patient (halfway) milestone for the NETTER-1 study, an international Phase III clinical trial evaluating the effect of Lutathera® in patients with inoperable progressive midgut carcinoid tumors. The primary endpoint of the trial is the assessmen...
Start of Pivotal Phase III trial for Lutathera® in cancer patients with progressive midgut carcinoid
Advanced Accelerator Applications (AAA) announces the initiation of an international Phase III clinical trial evaluating the effect of Lutathera in patients with inoperable progressive midgut carcinoid. The study will be conducted at multiple centres in Europe and North America. The first European p...